Route 92 Medical announces first commercial cases in Canada following Health Canada Medical Device license for advanced neurovascular portfolio.
Tag: Route 92 Medical
Route 92 Medical Announces $50 Million Growth Financing
New investor Sectoral Asset Management joins growth financing round to support acceleration of commercial growth April 7, 2026 WEST JORDAN, Utah— Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced a $50 million growth financing. New investor Sectoral Asset Management joined […]
Route 92 Medical Enrolls First Patient in SUMMIT RISE Study
SUMMIT RISE is expected to enroll up to 500 patients to evaluate the performance of Route 92 Medical’s neurovascular intervention device portfolio WEST JORDAN, Utah, March 9, 2026 – (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing […]
Route 92 Medical Files Patent Infringement Suit Against Balt
SAN MATEO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, filed a patent infringement lawsuit against Balt USA, LLC (Balt) alleging infringement of five U.S. patents held by Route 92 Medical that […]
Route 92 Medical Receives Australian Therapeutic Goods Administration Approval for its Portfolio of Neurovascular Interventional Products for Treating Patients with Acute Ischemic Stroke
Route 92 Medical receives Australian Therapeutic Goods Administration approval for its portfolio of neurovascular interventional products.
Route 92 Medical Gains EU and MDSAP Certification for its Neurovascular Stroke-Intervention-Focused Product Portfolio
Route 92 Medical announces EU and MDSAP certification for its neurovascular stroke-intervention-focused product portfolio.
Route 92 Medical Files Patent Infringement Suit Against Q’Apel Medical
SAN MATEO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today filed a patent infringement lawsuit against Q’Apel Medical alleging infringement of five U.S. patents held by Route 92 Medical, which protect the Tenzing® delivery catheter. The complaint was filed October 7, 2024, in the United States District Court for the District of Delaware.
Route 92 Medical Announces $50 Million Series F Extension Equity Financing
Funds from Novo Holdings will support global commercial expansion Novo Holdings’ Noel Jee joins Route 92 Board of Directors SAN MATEO, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced a […]
Route 92 Medical Announces FDA 510(k) Clearance for FreeClimb 54 Reperfusion System
Route 92 Medical announces FDA 510(k) clearance for its FreeClimb 54 reperfusion system, part of its growing portfolio of neurovascular devices.
Route 92 Medical Announces Completion of Enrollment in the SUMMIT MAX Clinical Trial
SAN MATEO, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the completion of enrollment in its 250-patient SUMMIT MAX clinical trial (NCT05018650) evaluating the safety and effectiveness of its HiPoint™ 88 […]
Recent
Popular
- No commented posts yet